Kornimate/medical-research-clean huggingface dataset:
double-blind randomized cross-over trial comparing metabolic effects of candesartan, hydrochlorothiazide and placebo

Conditions: Hypertension; Obesity

Summary: the purpose of this study is to investigate the effect of a 12-week candesartan treatment compared with hydrochlorothiazide on insulin sensitivity assessed with hyperinsulinemic euglycemic clamp.

to investigate the mechanisms underlaying the diabetes-preventing effect of candesartan with respect to possible impact on insulin sensitivity, beta cell function and adipose tissue function and distribution. for this purpose comparisons will be performed with hydrochlorothiazide and placebo treatment. it is hypothesized that candesartan will improve insulin sensitivity as compared to hydrochlorothiazide and possibly also in comparison with placebo and that this could be explained by altered fat tissue function or distribution or by an altered sympathetic to parasympathetic balance in the autonomic nervous system. hydrochlorthiazide is chosen as comparator because thiazides are a recommended firs-line therapy in hypertension. this drug class has some detrimental effects on glucose tolerance and in insulin sensitivity.

Eligibility criteria:
inclusion criteria: * male and female 18-70 years old * diagnosed hypertension and abdominal obesity (waist circumference greater than or equal to 102 cm (m) or 88 cm (f) exclusion criteria: * uncontrolled hypertension * treatment with more than two concomitant antihypertensive medications * diabetes mellitus * other endocrine disorder * severe liver disease * severely reduced renal function * malignant disease * alcohol or drug abuse * severe psychiatric illness * history of stroke, myocardial infarction, unstable angina pectoris, participation in another clinical trial less than two months prior to screening visit * treatment with anti-obesity drugs * anti-inflammatory drugs or immunosuppressive drugs

Keywords: metabolic hypertension abdominal obesity insulin sensitivity hyperinsulinemic euglycemic clamp
clinical and radiographic evaluation of a cross-shaped incision technique

Conditions: Clinical and Radiographic Effect; Thick-gingiva; Implant; Thin Gingiva

Summary: to evaluate a cross-shaped incision technique to thick-gingiva and thin-gingiva patients treated with implant-supported fixed prosthesis.

objective: to evaluate a cross-shaped incision technique to thick-gingiva and thin-gingiva patients treated with implant-supported fixed prosthesis. methods and materials: 55 patients received cross-shaped incision were assigned into thick-gingiva group (29 cases) and thin-gingiva group (26 cases). follow-up examination was carried out 3 and 12 months after final restoration. clinical and radiographic evaluation including gingival papilla height, modified plaque index, modified sulcus bleeding index, periodontal depth, and crestal marginal bone level were utilized.

Eligibility criteria:
inclusion criteria: 1. good general health, no chronic systemic diseases. 2. all subjects included in this study needed to have one missing premolar or molar teeth with adjacent natural teeth. 3. all subjects included in the study had been treated with one bone-level implant insertion in the premolar or molar region. exclusion criteria: 1. active periodontal infections. 2. heavy smoking habit (\>10 cigarettes per day).
safety and efficacy of secukinumab compared to etanercept in subjects with moderate to severe, chronic plaque-type psoriasis

Conditions: Chronic Plaque Psoriasis

Summary: this study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.


Eligibility criteria:
inclusion criteria: * subjects with chronic, plaque-type psoriasis for at least 6 months * must have moderate to severe psoriasis based on pasi greater than 12, iga greater than 3, and greater than 10% body surface area * must be inadequately controlled by prior treatments (topicals, phototherapy, and/or systemic therapies) exclusion criteria: * forms of psoriasis other than chronic, plaque-type (such as pustular, erythrodermic and guttate psoriasis) * drug induced psoriasis * use of other psoriasis treatments during the study * prior use of etanercept * prior use of secukinumab or any other drug that target il-17 (interleukin 17) or the il-17 receptor * pregnant or lactating women; women who do not agree to use contraception during the study and for 16 weeks after stopping treatment * significant medical problems such as uncontrolled high blood pressure, congestive heart failure, etc. * history of an ongoing, chronic or recurrent infection or evidence of tuberculosis * allergy to rubber or latex other protocol-defined inclusion/exclusion criteria may apply

Keywords: psoriasis, inflammatory skin disease, scaly patches psoriasis inflammatory skin disease
'' abdominal crunch positions with the others in terms of interspinous distance in adult patients ''

Conditions: Anesthesia, Spinal

Summary: the most important factor for ease of operation and safety during spinal anesthesia is the determination of the spinal space. increasing lumbar flexion facilitates access to the spinal space. traditionally, patients undergo spinal anesthesia with lateral or sitting lumbar flexion. in a study by martha l walker et al., the maximum extension of the knees, adduction of the hip, and a modified sitting position with the back flexion, ie, the abdominal crunch position, were found to be effective in increasing the flexion of the lumbar spine. in our study, we aimed to measure the interspinal distance with the abdominal crunch position with the help of ultrasonography (usg) and to compare the interspinal distance with the measurements obtained in traditional positions (sitting position and lateral decubitus).

interspinal distance will be measured by ultrasonography by 3 different positions, respectively, for the patients who will undergo elective surgery and meet the study criteria and give voluntary consent. this evaluation process is to record and compare the measurement results. patients will not undergo any interventional procedures. patients who have difficulty in positioning due to hip, femur, knee and tibial fractures or arthrosis and who cannot be communicated will not be included in the study. one hundred of patients over the age of 18 who will undergo elective surgery will be included in the study.

Eligibility criteria:
inclusion criteria: * patients over the age of 18 * undergo elective surgery exclusion criteria: * patients with vertebral anomaly * patient with not communicated
prospective endodontics database

Conditions: Apical Periodontitis

Summary: endodontic treatment is necessary after certain dental trauma or in the presence of a large carious lesion, associated with signs of irreversible pulpal inflammation. the treatment of apical periodontitis is a real public health issue. the endodontic success rate is between 68 and 85%. indeed, some studies show that systemic diseases such as diabetes can increase the prevalence and bone loss associated with apical periodontitis. other studies identify apical periodontitis as a factor that can potentiate symptoms caused by inflammatory diseases such as cardiovascular disease and diabetes by increasing the level of inflammatory cells in the blood. however, since 2014 the european society of endodontology has recommended establishing a higher level of evidence to ensure the link that these pathologies may have. for this, it is necessary to assess the criteria that may influence the healing of apical periodontitis. endodata has been developed by dental surgeons specializing in endodontics. the purpose of this software is to improve the clinical follow-up of patients and to establish a clinical and radiological database. in this context, the creation of a clinical database including data for all root canal treatment is of high interest.


Eligibility criteria:
inclusion criteria: * adult patient aged ≥ 18, * new patients received in consultation by students registered for a diploma in endodontics in one of the participating centres (brest, bordeaux, lyon, nancy, nantes, nice, paris, toulouse) or received by one of the private practitioners participating in the study; * patient with an indication for endodontic treatment or endodontic retreatment on at least one permanent tooth. exclusion criteria: * patient unable to understand the purpose and conduct of the study.
accuracy of accuhaler tester, ellipta tester and turbutester in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the goal of this observational study is to investigate the accuracy of accuhaler tester, ellipta tester and turbutester in patients with chronic obstructive pulmonary disease (copd). the main question it aims to answer is: • do accuhaler tester, ellipta tester, and turbutester demonstrate comparable accuracy to the in-check dial for assessing inspiratory inhalation force in copd patients?

this study is a cross-sectional study. copd patients aged 40 years or older will be included. peak inspiratory flow rate (pifr) will be assessed using in-check dial as the standard tool. pifr will be tested in each patient using accuhaler tester, ellipta tester and turbutester.

Eligibility criteria:
inclusion criteria: * copd diagnosis with confirmed by post-bronchodilator forced expiratory volume in 1 second (fev1)/forced vital capacity (fvc) \<0.7 * age 40 years or older * smoking history 10 pack-years or more exclusion criteria: * copd exacerbation within 3 months * oral or intravenous corticosteroid treatment within 6 weeks * inability to perform assessment of peak inspiratory flow rate * asthma * tracheostomy, invasive or noninvasive mechanical ventilation

Keywords: chronic obstructive pulmonary disease copd accuhaler tester ellipta tester turbutester peak inspiratory flow rate
ultrasound guided transversus abdominis plane block with ropivacaine vs placebo for abdominal hysterectomy: a double-blinded, randomized clinical trial

Conditions: Postoperative Pain and Postoperative Morphine Consumption After Abdominal Hysterectomy

Summary: a prospective double-blinded randomized clinical trial to test the effect of transversus abdominis plane block on postoperative pain and opoid consumption after abdominal hysterectomy. two groups of each 24 patients. all patients are given general anesthesia. the patients are randomized to have a ultrasound guided bilateral transversus abdominis plane block with either 2 x 20 ml 0,75 % ropivacaine or 2 x 20 ml of 0,9 saline. all patients are provided with a pca for self administration of morphine. pain score on visual analog scale, nausea and vomiting are monitored at 1, 2, 4, 6, 8 and 24 hours postoperatively as well as the total consumption of morphine after 24 hours.


Eligibility criteria:
inclusion criteria: * assigned to elective abdominal hysterectomy * must be able to understand and speak danish * must be able to give verbal and written consent exclusion criteria: * abuse of alcohol or medicin * daily treatment with opoids or glucocorticoids * allergy towards any kind of localanesthetic drug * intolerance toward morphine * psychiatric desease * age below 18
donor simvastatin treatment in organ transplantation

Conditions: Heart Failure; Respiratory Failure; Liver Failure; Kidney Failure; Transplantation

Summary: the aim of the study is to investigate the effects of donor simvastatin treatment on ischemia-reperfusion injury after heart transplantation.

the study hypothesis of the single center randomized double-blinded clinical trial is that donor simvastatin treatment reduces ischemia-reperfusion injury after heart transplantation. also, it potentially decreases natural immune activity, rejection activation and thus improves long-term prognosis. simvastatin is administered to heart and/or lung donors through the nasogastric tube 4-6 hours prior to organ harvesting. control organ donors do not receive simvastatin. the randomization and donor hospital instruction of the donor simvastatin treatment is performed by the transplant coordinator. all other caregivers and the transplant recipient are blinded to the treatment group allocation. the impact of donor simvastatin treatment is investigated and analyzed by several specific blood samples and biopsies that are taken from the recipient at the various time-points during the perioperative and postoperative phase. in heart transplant recipients (n=42 in the donor simvastatin treatment group and n=42 in the control group), the primary end-point is postoperative cardiac enzyme serum levels (tnt, tni, and ck-mb 1 hour, 6 hours, 12 hours and 24 hours after transplantation) and primary graft failure. secondary end-points include peri- and postoperative parameters hemodynamics, short- and long term survival, biopsy-proven rejections, rejection treatments, and chronic rejection at 1, 5, 10, and 20 years after transplantation. lung, kidney and liver transplant recipients that have received organs from donors randomized to the control group or donor simvastatin group will also be followed for ischemia-reperfusion injury, perioperative organ function, innate and adaptive immunity and patient survival.

Eligibility criteria:
inclusion criteria for a donor: * heart transplant donor * age 18-60 years * previously healthy * no cholesterol medication * normal echo with lvef \>45%, normal right ventricle and normal coronary angiography * pio2/fio2 \> 40kpa, normal chest radiograph and normal bronchoscopy in lung donors exclusion criteria for the heart/lung donor: * severe left ventricular hypertrophy \> 14 mm * high dose of inotropes (dopamine or dobutamine \> 20ug/kg/min or norepinephrine \>0.2 ug/kg/min) at the time of procurement * donor outside of the study country finland inclusion criteria for a transplant recipient: * age between 18-70 for heart transplant recipients * male or female * listed for heart, lung, kidney, or liver transplantation exclusive criteria for the recipient * systemic sepsis * a positive cross match

Keywords: transplantation simvastatin treatment ischemia-reperfusion injury rejection
inhaled budesonide in transient tachypnea of the newborn

Conditions: Respiratory Distress

Summary: background: transient tachypnea of the newborn (ttn) caused by lung edema resulting from delayed absorption of fetal alveolar lung fluid and is a common cause of admission of late preterm and full-term infants to neonatal intensive care units. infant born by c-section and those with perinatal asphyxia, umbilical cord prolapse or certain maternal condition (asthma, diabetes, or analgesia) are more prone to develop ttn. conventional treatment involves appropriate oxygen administration and continuous positive airway pressure in some cases. hastening the clearance of lung liquid should shorten the duration of the symptoms and reduce complications. objectives: this study aims to determine the effectiveness of inhaled budesonide in the treatment of this disorder through determining whether it reduces the duration of oxygen therapy and respiratory symptoms and shortens hospital stay in term infants with transient tachypnea of the newborn


Eligibility criteria:
inclusion criteria: * late preterm and term infants (post-menstrual age ≥ 34 weeks) delivered by cesarean section or vaginal delivery * diagnosis of transient tachypnea of the newborn * the need for continuous positive airway pressure (cpap) \>6 hours to obtain the oxygen saturation \>92% exclusion criteria: * meconium aspiration syndrome; * respiratory distress syndrome * congenital heart disease * non respiratory disorders causing tachypnea (polycythemia or hypoglycemia) resolving with treatment of the disorder * pneumonia by chest x-ray * suspected sepsis/bacteremia * prenatal steroids
detecting occult proximal humeral neck fractures through ct and mri tests of patients with greater tuberosity fractures

Conditions: Humeral Greater Tuberosity; Humeral Fractures/ Proximal; Fractures/ Occult

Summary: patients with greater tuberosity fractures is becoming increasingly common, as is the number of cases of humeral surgical neck fractures. this study investigated the relationship between size of greater tuberosity fragment and occurrence of humeral surgical neck fractures by using ct or mri tests.

some humeral surgical neck fractures can be detected through x-ray of shoulder in patients with greater tuberosity fractures. however, some fractures can not be find through conventional x-ray in such patients unless broader ct or mri tests are required to confirm diagnoses of humeral surgical neck fractures.

Eligibility criteria:
inclusion criteria: * patients 18 years or older with greater tuberosity fractures and shoulder dislocation/ or not who were acute injured were included exclusion criteria: * patients with ipsilateral previous proximal humeral fractures and obviously proximal humeral fractures were excluded。

Keywords: occult proximal humeral neck fractures greater tuberosity shoulder dislocation
adaptive auditive cueing as a therapy for freezing of gait in parkinson patients

Conditions: Parkinson Disease

Summary: the first goal of the study is to investigate whether an algorithm can reliably detect freezing of gait (fog) in parkinson patients based on participant gait data generated by a pressure insole. the second goal is to investigate whether auditive cueing (ac) based on such a detection reduces the frequency and length of fog episodes in those participants. the study will be conducted per good clinical practice principles.


Eligibility criteria:
inclusion criteria: * must have more than 1 fog episode/day * must be patient in ziekenhuis oost limburg (zol) exclusion criteria: * not able to speak dutch * cannot give informed consent (mental health)
study to evaluate efficacy and safety of pennel capsule in the patients with chronic liver disease

Conditions: Chronic Liver Disease

Summary: the drug in this study is combined product of biphenyl dimethyl dicarboxylate (ddb) and garlic oil. this components showed synergistic enhancing effects in previous tests. in phase 2 test, 6 cap three times a day dosage (2cap t.i.d) is better than other dosage. based on above, this study is phase 3 test to prove efficacy and safety of pennel.


Eligibility criteria:
inclusion criteria: * patients diagnosed with chronic hepatitis by biopsy * patients over 20, under 65 years of age. * patients with abnormal transaminase value. exclusion criteria: * pregnant and lactating women. * patients who have any history of esophageal bleeding, hepatic encephalopathy, ascites. * diabetes, thyroid dysfunction, fatty liver, liver cancer patients. * toxic hepatitis, alcoholic hepatitis. * total bilirubin value more than 3.0 mg/dl. * albumin value less than 3.0 g/dl. * patients who participating in other study about drug.
music intervention in chronic pain patients

Conditions: Chronic Pain; Anxiety; Well-Being, Psychological

Summary: the goal of this randomized controlled trial is to evaluate the efficacy of a personalized music intervention program to improve the condition of individuals suffering from chronic pain. the main objective is to evaluate if the intervention program will significantly reduce participants composite score of pain, anxiety, and well-being (reversed) as evaluated by the edmonton symptom assessment scale (esas-r) immediately after the intervention, and whether this improvement will be significantly greater than that of control sessions.

the participants (n = 36) will be randomized into two groups. the intervention will last for 4 weeks. once per week for the first 2 weeks, the first group will have a personalized musical intervention in person on the university campus and will evaluate their pain, anxiety, and well-being scores before and after each session. for the following 2 weeks, the participants will have online access to their music sessions and will also assess their levels of pain, anxiety, and well-being before and after each intervention session. the second group (control group) will evaluate their pain, anxiety, and well-being scores 20 minutes apart once per week for the first 2 weeks.participants will continue their daily activities between the two measurement times. during the next 2 weeks, the participants will listen to online musical sessions once per week and will again evaluate their levels of pain, anxiety, and well-being before and after each intervention session. the main objective of this randomized controlled trial is to evaluate the immediate effect of a personalized music intervention for the experimental group/in-person intervention on a composite score of pain, anxiety, and well-being (reversed), compared to the control group/no intervention sessions, as measured by the esas-r. the secondary objective is to assess the evolution of each of these three esas-r variables (pain, anxiety, well-being) from pre-test to post-test compared with changes in these variables in the control group/no intervention sessions. the differences between in-person musical interventions and online musical sessions, as well as the feasibility and adherence of participants to an online music intervention program, will also be assessed. furthermore, the effect of a music session preceded by a period of relaxation compared to the effect of a musical session alone, and the experiential dimensions experienced, will be evaluated. at the end of the experiment, both groups will be interviewed to analyze their comments regarding the interventions.

Eligibility criteria:
inclusion criteria: * aged 18 years and older; * suffering from chronic pain and actively attending the pain clinic at the chu de québec-université laval; * have an email and be able to respond to online questionnaires using a computer, tablet, or phone; * have satisfactory or corrected hearing; * understand french; * be able to travel to université laval. exclusion criteria: * none

Keywords: chronic pain music anxiety well-being
cosmetic outcome, patient-reported outcomes, and reconstruction-related complications in breast cancer women treated with or without post-mastectomy radiation therapy

Conditions: Breast Cancer Female

Summary: this study aim to investigate the breast reconstruction outcome after mastectomy with or without radiation therapy from the patient's point of view.


Eligibility criteria:
inclusion criteria: * pathologically confirmed invasive breast carcinoma * women who underwent mastectomy and breast reconstruction * good performance status (ecog 0-1) exclusion criteria: * recurrent breast cancer * history of ipsilateral breast irradiation